(CercleFinance.com) – The biopharmaceutical company Aelis Farma announced on Monday that it had ended the first half with cash of 39.8 million euros, which gives this brain disease specialist financial visibility until the end of 2024.
In its press release, the Bordeaux company recalls that this figure includes the net proceeds of 22.5 million euros from the fundraising carried out on the occasion of its IPO on Euronext, last February.
Over the first six months of the year, its operating loss amounted to around 4.6 million euros, against a profit of 4.6 million euros a year earlier.
Aelis explains these losses by the start of its phase 2b study on AEF0117, but also by the timing of the license option agreement concluded with Indivior.
In the first half, the company recorded income from ordinary activities of 4.3 million euros, including two million euros corresponding to the share of income related to the sub-license option contract with Indivior, a specialist in processing addictions, for AEF0117 in cannabis use disorders
To this were added 2.3 million euros of other income from ordinary activities consisting of the research tax credit and operating subsidies.
Aelis indicates that the second part of the year promises to be just as dynamic, in particular with the expected passage of its second drug candidate, AEF0217, into phase 1/2 in subjects with trisomy 21.
As a reminder, this compound has shown its ability to completely reverse the deficits in several animal models of cognitive disorders, including Down syndrome.